Roche presents final Phase 1b data on its investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma at EADO 2014

BRIM7 study shows that cobimetinib and Zelboraf (vemurafenib) can be co-administered and provided a median progression-free survival of 13.7 months in BRAF inhibitor-naive patients. Confirmatory Phase 3 study, coBRIM, is ongoing and is expected to report later this year. Roche announced today that important new data have been presented for its investigational MEK inhibitor cobimetinib (GDC-0973) in combination with Zelboraf, a BRAF inhibitor, as a potential treatment option for patients with advanced BRAFV600 mutation-positive metastatic melanoma. These data were presented at the 10th European Association of Dermato Oncology (EADO) Congress in Vilnius, Lithuania.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news